John Houston, Arvinas CEO

Arv­inas re­ports de­lay for Pfiz­er-part­nered pro­tein degra­da­tion pro­gram

Arv­inas’ stock plunged about 17% on Mon­day af­ter the com­pa­ny re­vealed an­oth­er de­lay for its Pfiz­er-part­nered pro­tein de­grad­er in com­bi­na­tion with Ibrance, al­so known as pal­bo­ci­clib.

A re­cent analy­sis of an on­go­ing Phase Ib study in first-line metasta­t­ic breast can­cer pa­tients showed an “in­crease in pal­bo­ci­clib ex­po­sure” that CEO John Hous­ton told End­points News is “prob­a­bly just out­side the range of what we’d ex­pect to be nor­mal.” That led the com­pa­nies to pro­pose a mod­i­fi­ca­tion to the planned Phase III VER­I­TAC-3 study, which will like­ly set the launch back to the sec­ond half of this year, Arv­inas an­nounced in an SEC fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.